[Clinical heterogeneity of Alzheimer's disease. Different clinical profiles can predict the progression rate].
BACKGROUND
Alzheimer's disease (AD) is a degenerative dementia that may disclose different cognitive, behavioral, psychiatric and functional symptoms since onset. These distinct cognitive profiles support the conception of clinical heterogeneity and account for AD's highly variable rate of progression. In spite of strict diagnostic criteria NINCS ADRDA's and DSM IV the clinical certainty is only about 85%. Mayeux define 4 subtypes: a). Benign: mild cognitive and functional impairment without focal signs and late onset behavioral signs, slow progression; b). Myoclonic: usually of presenile onset with severe cognitive deterioration, mutism and early onset myoclonus; c). Extrapyramidal: early onset akineto rigid signs with severe cognitive, behavioral and psychiatric involvement; d). Typical: gradual and progressive cognitive, behavioral and functional impairment. The differentiation of these subtypes will allow us to define discrete patterns of progression, to define prognostic subgroups, and to homogenize them for clinical research and drug trials.


METHODS
We examined 1000 charts of probable AD patients from the Santojanni Center. We found 42% extrapyramidal, 35% typical, 15% benign and 8% myoclonic. The early onset of parkinsonism and myoclonus predict a rapidly evolving cognitive impairment and a more severe rate of progression with psychiatric disorders and dependency in activities of daily living. (DADL) Patients with low level of education, low cognitive performance at entry as well as those with rapid rate of cognitive deterioration had a faster rate of progression to DADL.


CONCLUSIONS
Delusions, low level of education, extrapyramidal signs and motor hyperactivity but not hallucinations, and anosognosia were the best non cognitive predictors of DADL.
Mangone
C A
CA
Centro de Asistencia e Investigación del Deterioro Cognitivo, Hospital Santojani, Buenos Aires, Argentina. camangone@fibertel.com.ar
D000203:Activities of Daily Living; D017668:Age of Onset; D000544:Alzheimer Disease / Q000145:classification* / Q000150:complications / Q000453:epidemiology / Q000503:physiopathology; D001480:Basal Ganglia Diseases / Q000209:etiology; D002531:Cerebellum / Q000503:physiopathology; D018450:Disease Progression; D004522:Educational Status; D005625:Frontal Lobe / Q000503:physiopathology; D006212:Hallucinations / Q000209:etiology; D006801:Humans; D006948:Hyperkinesis / Q000209:etiology; D001523:Mental Disorders / Q000209:etiology; D009207:Myoclonus / Q000209:etiology; D009460:Neurologic Examination; D000857:Olfaction Disorders / Q000209:etiology; D010468:Perceptual Disorders / Q000209:etiology; D012720:Severity of Illness Index; D013997:Time Factors